#Oxford #Boehringer Ingelheim #UK #Brainomix #e-Lung Technology

Brainomix's e-Lung Technology: A Game Changer in Pulmonary Fibrosis Detection

In a significant milestone, Brainomix, an innovative company specializing in AI-driven imaging solutions, is set to showcase compelling validation of its e-Lung technology at the upcoming American Thoracic Society (ATS) Conference in San Francisco. This groundbreaking technology plays a pivotal role in the precise identification of progressive pulmonary fibrosis, a serious lung condition that, when untreated, can drastically shorten a patient's life.

The e-Lung software, which has garnered FDA clearance, is designed to automatically analyze CT biomarkers for patients suffering from interstitial lung disease (ILD). This software represents a leap forward in how doctors can manage patient care through its sophisticated AI and machine learning algorithms. It not only improves tracking of disease progression but also equips clinicians with a powerful tool for better decision-making.

The validation comes from a collaborative effort with Boehringer Ingelheim, a leader in pulmonary fibrosis therapies. Through this partnership, Brainomix had exclusive access to the INBUILD clinical trial's extensive dataset, allowing for an in-depth quantitative CT analysis. The results underscored the e-Lung technology's reliability and sensitivity in diagnosing progressive pulmonary fibrosis, verifying its ability to predict patient risks with remarkable accuracy.

At the forefront of these findings, Dr. Susanne Stowasser from Boehringer Ingelheim emphasized the importance of collaborative ventures aimed at enhancing patient outcomes. She remarked, “Our collaboration with Brainomix helps in creating breakthroughs that advance imaging biomarkers for better prognostication and therapeutic responses, ultimately enhancing patient care.”

During the ATS conference, Brainomix has scheduled three core presentations led by respected professionals, including Prof Anand Devaraj and Dr. Peter George from the Royal Brompton Hospital in London. These sessions will cover key studies examining the relationship between e-Lung biomarkers and the trajectory of progressive pulmonary fibrosis.

One notable study indicates that e-Lung biomarkers independently forecast future disease progression, providing critical insights beyond the Conventional UIP status on CT scans. Another study illustrates that baseline quantitative CT analyses can accurately predict forced vital capacity decline rates, offering significant implications for patient management in clinical settings. An additional investigation into the effect of Nintedanib on quantitative CT further solidifies the software's value.

As pulmonary fibrosis poses considerable challenges in early diagnosis—often delaying six months to two years—early intervention is crucial. Dr. Peter George stressed how e-Lung's superior sensitivity compared to traditional visual analysis can lead to better treatment strategies. “Accurate identification of changes over time can empower physicians to make informed treatment decisions sooner, enhancing the quality of care for at-risk patients,” he stated.

Brainomix, having emerged from the prestigious University of Oxford, is committed to revolutionizing the management of lung diseases through innovative imaging solutions. Their initiatives have been bolstered by a strategic partnership with leading pulmonary sites, which validates the e-Lung technology in real-world settings.

The potential of the e-Lung technology to redefine patient care in progressive pulmonary fibrosis is unmistakable. Attendees of the ATS conference can visit Brainomix’s booth (#1563) to learn more about this transformative technology and its applications in clinical practice. As the medical community continues to embrace AI and advanced imaging solutions, Brainomix stands at the forefront, promising a brighter future for patients battling chronic lung conditions.

In summary, Brainomix's e-Lung technology not only heralds a new chapter in the diagnosis and management of pulmonary fibrosis but also reinforces the necessity for accurate and timely intervention in a field where every moment counts.